An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD)
Phase of Trial: Phase I/II
Latest Information Update: 04 Jul 2017
At a glance
- Drugs SRX 246 (Primary)
- Indications Huntington's disease
- Focus Adverse reactions
- Sponsors Azevan Pharmaceuticals
- 14 Jun 2016 Planned End Date changed from 1 Apr 2018 to 1 Jun 2018.
- 14 Jun 2016 Planned primary completion date changed from 1 Apr 2018 to 1 Jun 2018.
- 14 Jun 2016 Status changed from not yet recruiting to recruiting.